Janus kinase inhibitor-Tofacitinib associated with pemphigus: an analysis of the FDA adverse event reporting system data
CONCLUSION: Pemphigus, a rare and potentially fatal adverse event, was found to occur more frequently in patients receiving Tofacitinib. High-risk individuals were identified as female, age between 40-49, or with rheumatoid arthritis. Medication, adverse events, and underlying disease conditions were identified as potential contributing factors. Rheumatology and dermatology specialists should exercise increased vigilance in clinical practice.PMID:37722813 | DOI:10.1080/14740338.2023.2248872
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Li Wang Bin Zhao Source Type: research
More News: Arthritis | Canada Health | Dermatology | Drugs & Pharmacology | Pemphigus | Rheumatoid Arthritis | Rheumatology | Skin | Sports Medicine